IPI-504 News
Most Popular IPI-504 Story
AZ returns rights to two oncology programs
AstraZeneca has handed back the rights to two oncology programs it picked up in the 2007 acquisition of MedImmune. Infinity Pharmaceuticals gets the full rights to IPI-504 and IPI-493, both of which... Read more...
Latest Headlines
- April 15, 2009
- December 11, 2008
- July 16, 2008
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
